Ascendis 
Welcome,         Profile    Billing    Logout  
 5 Products   11 Diseases  5 Products   13 Trials   223 News 
19 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Skytrofa (lonapegsomatropin-tcgd) / Ascendis
2021-004313-39: An extension study to check the safety of once weekly lonapegsomatropin when given for a long time in adults with growth hormone deficiency. Μία μελέτη επέκτασης για τον έλεγχο της ασφάλειας της άπαξ εβδομαδιαίως δόσης Lonapegsomatropin όταν χορηγείται για μεγάλο χρονικό διάστημα σε ενήλικες με ανεπάρκεια αυξητικής ορμόνης

Not yet recruiting
3
240
Europe
lonapegsomatropin drug product, ACP-011, Powder and solvent for solution for injection
Ascendis Pharma Endocrinology Division A/S, Ascendis Pharma Endocrinology Division A/S
Adult Growth Hormone Deficiency (AGHD) Ανεπάρκεια Αυξητικής Ορμόνης Ενηλίκων (AGHD), Lack of growth hormone in the body Έλλειψη αυξητικής ορμόνης στο σώμα, Diseases [C] - Hormonal diseases [C19]
 
 
enliGHten, NCT03344458 / 2017-003410-20: A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial

Completed
3
298
Europe, US, RoW
TransCon hGH
Ascendis Pharma A/S
Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency, Pituitary Diseases
02/23
02/23
foresiGHt, NCT04615273 / 2020-000929-42: A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

Completed
3
264
Europe, Canada, Japan, US, RoW
Lonapegsomatropin, Placebo, Somatropin
Ascendis Pharma Endocrinology Division A/S
Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
11/23
12/23
NCT05171855 / 2021-004313-39: A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

Completed
3
233
Europe, Canada, Japan, US, RoW
Lonapegsomatropin, ACP-011
Ascendis Pharma Endocrinology Division A/S, Ascendis Pharma Endocrinology Division A/S
Adult Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
12/24
12/24
COACH, NCT06433557: A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia

Active, not recruiting
2
22
Europe
Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections
Ascendis Pharma Growth Disorders A/S
Achondroplasia
09/25
09/27
NCT05690386: A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome

Active, not recruiting
2
48
US
Lonapegsomatropin, Somatropin
Ascendis Pharma Endocrinology Division A/S
Turner Syndrome
12/24
12/27
SkyPASS, NCT05775523: A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin

Recruiting
N/A
500
US
No intervention
Ascendis Pharma Endocrinology Division A/S
Growth Hormone Deficiency
03/33
03/33
SkybriGHt, NCT05820672: A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

Recruiting
N/A
900
US
No intervention
Ascendis Pharma Endocrinology Division A/S
Growth Hormone Deficiency
03/33
03/33
onvapegleukin alfa (TransCon IL-2 β/γ) / Ascendis
2022-001191-34: A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination with Pembrolizumab and/or Chemotherapy or TransCon TLR7/8 Agonist in Adult Participants with Locally Advanced or Metastatic Solid Tumor Malignancies

Not yet recruiting
2
287
Europe
TransCon IL-2 β/γ, KEYTRUDA, TransCon TLR7/8 Agonist, ACP-016, ACP-017, Concentrate for solution for infusion, Suspension for injection
Ascendis Pharma Oncology Division A/S, Ascendis Pharma Oncology Division A/S
locally advanced or metastatic solid tumor malignancies, platinum resistant ovarian cancer, post-anti-pd-1 melanoma, second line or later cervical cancer, neoadjuvant melanoma and neoadjuvant non-small cell lung cancer, Locally Advanced or Metastatic Solid Tumor Malignancies, Diseases [C] - Cancer [C04]
 
 
BelieveIT-201, NCT05980598: TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma

Completed
2
27
Europe, US, RoW
TransCon TLR7/8 Agonist, Pembrolizumab, Keytruda™, TransCon IL-2 β/γ
Ascendis Pharma A/S
Head and Neck Neoplasms
12/24
03/25
IL Believe, NCT05081609 / 2022-001191-34: A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Recruiting
1/2
345
Europe, Canada, US, RoW
TransCon IL-2 β/γ, Pembrolizumab, Chemotherapy drug, TransCon TLR7/8 Agonist, Surgery, Trastuzumab, Trastuzumab emtansine (T-DM1)
Ascendis Pharma Oncology Division A/S, Ascendis Pharma Oncology Division A/S
Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer, Post Anti-PD-1 Melanoma, 2L+ Cervical Cancer, Neoadjuvant Melanoma, Neoadjuvant Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Small Cell Lung Cancer, Third Line or Later (3L+) HER2+ Breast Cancer, Second or Third Line (2L/3L) Cervical Cancer, Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)
08/27
08/29
resiquimod SR (TransCon TLR7/8 Agonist) / Ascendis
2021-001403-33: A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors Estudio en fase I/II, abierto, de escalada de dosis y ampliación de la dosis del agonista de TLR7/8 TransCon, en monoterapia o en combinación con pembrolizumab, en participantes con tumores sólidos malignos localmente avanzados o metastásicos

Not yet recruiting
1/2
220
Europe
TransCon TLR7/8 Agonist, ACP-017, Suspension for injection, Concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion
Ascendis Pharma Oncology Division A/S, Ascendis Pharma Oncology Division A/S
Locally advanced or metastatic solid tumor malignancies Tumores sólidos malignos localmente avanzados o metastásicos, Cancer Cáncer, Diseases [C] - Cancer [C04]
 
 
transcendIT-101, NCT04799054 / 2021-001403-33: A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

Active, not recruiting
1/2
188
Europe, US, RoW
TransCon TLR7/8 Agonist, Pembrolizumab
Ascendis Pharma Oncology Division A/S, Ascendis Pharma Oncology Division A/S
Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma HNSCC, HPV-associated Cancers, Neoadjuvant Melanoma, Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)
01/26
03/26
Yorvipath (palopegteriparatide) / Ascendis
2020-003380-26: PaTHway TRIAL: A Clinical Trial to Investigate the Safety and Effectiveness of TransCon PTH Administered as an Injection Under the Skin in Adults with Hypoparathyroidism.

Not yet recruiting
3
84
Europe
TransCon PTH low-dose pen, TransCon PTH mid-dose pen, TransCon PTH high-dose pen, [TransCon PTH], Solution for injection in pre-filled pen
Ascendis Pharma Bone Diseases A/S, Ascendis Pharma Bone Disease A/S, Ascendis Pharma Bone Diseases A/S
Hypoparathyroidism in Adults, Hypoparathyroidism is a disease where the parathyroid hormone production or activity is reduced., Diseases [C] - Hormonal diseases [C19]
 
 
PaTHway, NCT04701203 / 2020-003380-26: A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism

Completed
3
84
Europe, Canada, US
TransCon PTH, Placebo
Ascendis Pharma Bone Diseases A/S, Ascendis Pharma Bone Diseases A/S
Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
01/22
01/25
NCT05387070: PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

Recruiting
3
76
RoW
TransCon PTH, placebo
Visen Pharmaceuticals (Shanghai) Co., Ltd.
Hypoparathyroidism, Parathyroid Hormone Deficiency, Endocrine System Diseases, Parathyroid Diseases
12/22
12/25
2018-004815-33: PaTH Forward: a study to investigate the safety and efficacy of TransCon PTH administered as an injection under the skin daily in adults with hypoparathyroidism.

Ongoing
2
40
Europe, RoW
TransCon PTH low-dose pen, TransCon PTH mid-dose pen, TransCon PTH high-dose pen, TransCon PTH, Solution for injection in pre-filled pen
Ascendis Pharma Bone Diseases A/S, Ascendis Pharma Bone Disease A/S, Ascendis Pharma Bone Diseases A/S
Hypoparathyroidism (HP) in Adults, Reduction of secretion or activity of parathyroid hormone (PTH) in adults., Diseases [C] - Hormonal diseases [C19]
 
 
PaTH Forward, NCT04009291: A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

Completed
2
59
Europe, Canada, US
TransCon PTH, Placebo for TransCon PTH
Ascendis Pharma A/S
Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
03/20
04/25
NCT05654701: Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism

Approved for marketing
N/A
NA
Palopegteriparatide (TransCon PTH)
Ascendis Pharma Bone Diseases A/S, Clinigen Healthcare Ltd
Hypoparathyroidism
 
 
TransCon VEGF-TKI / Ascendis
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Skytrofa (lonapegsomatropin-tcgd) / Ascendis
2021-004313-39: An extension study to check the safety of once weekly lonapegsomatropin when given for a long time in adults with growth hormone deficiency. Μία μελέτη επέκτασης για τον έλεγχο της ασφάλειας της άπαξ εβδομαδιαίως δόσης Lonapegsomatropin όταν χορηγείται για μεγάλο χρονικό διάστημα σε ενήλικες με ανεπάρκεια αυξητικής ορμόνης

Not yet recruiting
3
240
Europe
lonapegsomatropin drug product, ACP-011, Powder and solvent for solution for injection
Ascendis Pharma Endocrinology Division A/S, Ascendis Pharma Endocrinology Division A/S
Adult Growth Hormone Deficiency (AGHD) Ανεπάρκεια Αυξητικής Ορμόνης Ενηλίκων (AGHD), Lack of growth hormone in the body Έλλειψη αυξητικής ορμόνης στο σώμα, Diseases [C] - Hormonal diseases [C19]
 
 
enliGHten, NCT03344458 / 2017-003410-20: A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial

Completed
3
298
Europe, US, RoW
TransCon hGH
Ascendis Pharma A/S
Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency, Pituitary Diseases
02/23
02/23
foresiGHt, NCT04615273 / 2020-000929-42: A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

Completed
3
264
Europe, Canada, Japan, US, RoW
Lonapegsomatropin, Placebo, Somatropin
Ascendis Pharma Endocrinology Division A/S
Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
11/23
12/23
NCT05171855 / 2021-004313-39: A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

Completed
3
233
Europe, Canada, Japan, US, RoW
Lonapegsomatropin, ACP-011
Ascendis Pharma Endocrinology Division A/S, Ascendis Pharma Endocrinology Division A/S
Adult Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
12/24
12/24
COACH, NCT06433557: A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia

Active, not recruiting
2
22
Europe
Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections
Ascendis Pharma Growth Disorders A/S
Achondroplasia
09/25
09/27
NCT05690386: A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome

Active, not recruiting
2
48
US
Lonapegsomatropin, Somatropin
Ascendis Pharma Endocrinology Division A/S
Turner Syndrome
12/24
12/27
SkyPASS, NCT05775523: A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin

Recruiting
N/A
500
US
No intervention
Ascendis Pharma Endocrinology Division A/S
Growth Hormone Deficiency
03/33
03/33
SkybriGHt, NCT05820672: A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

Recruiting
N/A
900
US
No intervention
Ascendis Pharma Endocrinology Division A/S
Growth Hormone Deficiency
03/33
03/33
onvapegleukin alfa (TransCon IL-2 β/γ) / Ascendis
2022-001191-34: A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination with Pembrolizumab and/or Chemotherapy or TransCon TLR7/8 Agonist in Adult Participants with Locally Advanced or Metastatic Solid Tumor Malignancies

Not yet recruiting
2
287
Europe
TransCon IL-2 β/γ, KEYTRUDA, TransCon TLR7/8 Agonist, ACP-016, ACP-017, Concentrate for solution for infusion, Suspension for injection
Ascendis Pharma Oncology Division A/S, Ascendis Pharma Oncology Division A/S
locally advanced or metastatic solid tumor malignancies, platinum resistant ovarian cancer, post-anti-pd-1 melanoma, second line or later cervical cancer, neoadjuvant melanoma and neoadjuvant non-small cell lung cancer, Locally Advanced or Metastatic Solid Tumor Malignancies, Diseases [C] - Cancer [C04]
 
 
BelieveIT-201, NCT05980598: TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma

Completed
2
27
Europe, US, RoW
TransCon TLR7/8 Agonist, Pembrolizumab, Keytruda™, TransCon IL-2 β/γ
Ascendis Pharma A/S
Head and Neck Neoplasms
12/24
03/25
IL Believe, NCT05081609 / 2022-001191-34: A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Recruiting
1/2
345
Europe, Canada, US, RoW
TransCon IL-2 β/γ, Pembrolizumab, Chemotherapy drug, TransCon TLR7/8 Agonist, Surgery, Trastuzumab, Trastuzumab emtansine (T-DM1)
Ascendis Pharma Oncology Division A/S, Ascendis Pharma Oncology Division A/S
Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer, Post Anti-PD-1 Melanoma, 2L+ Cervical Cancer, Neoadjuvant Melanoma, Neoadjuvant Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Small Cell Lung Cancer, Third Line or Later (3L+) HER2+ Breast Cancer, Second or Third Line (2L/3L) Cervical Cancer, Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)
08/27
08/29
resiquimod SR (TransCon TLR7/8 Agonist) / Ascendis
2021-001403-33: A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors Estudio en fase I/II, abierto, de escalada de dosis y ampliación de la dosis del agonista de TLR7/8 TransCon, en monoterapia o en combinación con pembrolizumab, en participantes con tumores sólidos malignos localmente avanzados o metastásicos

Not yet recruiting
1/2
220
Europe
TransCon TLR7/8 Agonist, ACP-017, Suspension for injection, Concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion
Ascendis Pharma Oncology Division A/S, Ascendis Pharma Oncology Division A/S
Locally advanced or metastatic solid tumor malignancies Tumores sólidos malignos localmente avanzados o metastásicos, Cancer Cáncer, Diseases [C] - Cancer [C04]
 
 
transcendIT-101, NCT04799054 / 2021-001403-33: A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

Active, not recruiting
1/2
188
Europe, US, RoW
TransCon TLR7/8 Agonist, Pembrolizumab
Ascendis Pharma Oncology Division A/S, Ascendis Pharma Oncology Division A/S
Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma HNSCC, HPV-associated Cancers, Neoadjuvant Melanoma, Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)
01/26
03/26
Yorvipath (palopegteriparatide) / Ascendis
2020-003380-26: PaTHway TRIAL: A Clinical Trial to Investigate the Safety and Effectiveness of TransCon PTH Administered as an Injection Under the Skin in Adults with Hypoparathyroidism.

Not yet recruiting
3
84
Europe
TransCon PTH low-dose pen, TransCon PTH mid-dose pen, TransCon PTH high-dose pen, [TransCon PTH], Solution for injection in pre-filled pen
Ascendis Pharma Bone Diseases A/S, Ascendis Pharma Bone Disease A/S, Ascendis Pharma Bone Diseases A/S
Hypoparathyroidism in Adults, Hypoparathyroidism is a disease where the parathyroid hormone production or activity is reduced., Diseases [C] - Hormonal diseases [C19]
 
 
PaTHway, NCT04701203 / 2020-003380-26: A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism

Completed
3
84
Europe, Canada, US
TransCon PTH, Placebo
Ascendis Pharma Bone Diseases A/S, Ascendis Pharma Bone Diseases A/S
Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
01/22
01/25
NCT05387070: PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

Recruiting
3
76
RoW
TransCon PTH, placebo
Visen Pharmaceuticals (Shanghai) Co., Ltd.
Hypoparathyroidism, Parathyroid Hormone Deficiency, Endocrine System Diseases, Parathyroid Diseases
12/22
12/25
2018-004815-33: PaTH Forward: a study to investigate the safety and efficacy of TransCon PTH administered as an injection under the skin daily in adults with hypoparathyroidism.

Ongoing
2
40
Europe, RoW
TransCon PTH low-dose pen, TransCon PTH mid-dose pen, TransCon PTH high-dose pen, TransCon PTH, Solution for injection in pre-filled pen
Ascendis Pharma Bone Diseases A/S, Ascendis Pharma Bone Disease A/S, Ascendis Pharma Bone Diseases A/S
Hypoparathyroidism (HP) in Adults, Reduction of secretion or activity of parathyroid hormone (PTH) in adults., Diseases [C] - Hormonal diseases [C19]
 
 
PaTH Forward, NCT04009291: A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

Completed
2
59
Europe, Canada, US
TransCon PTH, Placebo for TransCon PTH
Ascendis Pharma A/S
Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
03/20
04/25
NCT05654701: Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism

Approved for marketing
N/A
NA
Palopegteriparatide (TransCon PTH)
Ascendis Pharma Bone Diseases A/S, Clinigen Healthcare Ltd
Hypoparathyroidism
 
 
TransCon VEGF-TKI / Ascendis
No trials found

Download Options